Log in

NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Forecast & News

$6.70
-0.20 (-2.90 %)
(As of 12/15/2019 01:00 AM ET)
Today's Range
$6.58
Now: $6.70
$6.96
50-Day Range
$3.11
MA: $5.45
$8.00
52-Week Range
$2.25
Now: $6.70
$9.50
Volume44,277 shs
Average Volume939,523 shs
Market Capitalization$24.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-8869

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.65 million
Book Value$3.08 per share

Profitability

Net Income$-10,810,000.00

Miscellaneous

Employees11
Market Cap$24.39 million
Next Earnings Date3/6/2020 (Estimated)
OptionableNot Optionable

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.


Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its quarterly earnings data on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The specialty pharmaceutical company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.19 million. View Eyegate Pharmaceuticals' Earnings History.

When is Eyegate Pharmaceuticals' next earnings date?

Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Eyegate Pharmaceuticals.

Has Eyegate Pharmaceuticals been receiving favorable news coverage?

Media stories about EYEG stock have trended positive on Sunday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View News Stories for Eyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 252,600 shares, an increase of 2,451.5% from the November 14th total of 9,900 shares. Based on an average daily volume of 307,200 shares, the days-to-cover ratio is presently 0.8 days. Currently, 7.8% of the shares of the company are sold short. View Eyegate Pharmaceuticals' Current Options Chain.

Who are some of Eyegate Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyegate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Canopy Growth (CGC), Arca Biopharma (ABIO), Anavex Life Sciences (AVXL) and Novavax (NVAX).

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen From, Pres, CEO & Director (Age 56)
  • Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
  • Mr. Michael P. Manzo, VP of Engineering (Age 60)
  • Ms. Sarah Romano, Chief Financial Officer
  • Dr. MaryJane Rafii Ph.D., Consultant

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $6.70.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $24.39 million and generates $1.65 million in revenue each year. The specialty pharmaceutical company earns $-10,810,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.View Additional Information About Eyegate Pharmaceuticals.

What is Eyegate Pharmaceuticals' official website?

The official website for Eyegate Pharmaceuticals is http://www.eyegatepharma.com/.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.


MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  369 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  655
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel